Q-omics provides the consensus-scored RUFY1 profile across patient tissues and cancer cell-line models. RUFY1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RUFY1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RUFY1 protein abundance shows 28,068 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, KIRC, and LSCC as cancer lineages where RUFY1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RUFY1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RUFY1 survival associations across molecular data types. RUFY1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RUFY1 RNA expression–survival associations across cancer types. High RUFY1 expression shows unfavorable associations in KICH, LUSC, LGG and LIHC, but favorable associations in KIRC and SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RUFY1 RNA expression.
This table summarizes RUFY1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RUFY1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RUFY1 shows lower tumor expression in LUSC and KICH and higher tumor expression in KIRC, LIHC, BRCA and KIRP. The KIRC box plot shows higher RUFY1 RNA expression in tumor versus normal tissue (log2 FC = +0.711, t-test p < 0.001).
This table shows molecular features associated with RUFY1 in patient tissues and cancer cell lines. In patient samples, RUFY1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RUFY1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
